← Leaderboards
Amy Elizabeth Taylor
University Of California, San Diego
$127,590
Attributed
$127,590
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $51.8K · FY2019–22$100K$75K$50K$25K$0
'19
'20
'21
'22
Funding mix
By agency
NIH$127,590 · 1
By mechanism
F30$127,590 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Diego
Same institution · by research overlap
- Maurice S Swanson$17,857,475
- Eugene Wei-Ming Yeo$40,192,855
- Joseph G Gleeson$42,611,227
- Clotilde Lagier-Tourenne$11,959,245
- Michael G Rosenfeld$73,496,650
Others in their field
Other Emerging Leaders on “Adult”
- Beth Baseler · Leidos Biomedical Research, Inc.$127,607,354
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$93,592,175
- Susan M Landau · University Of California Berkeley$47,252,026
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$42,295,422
- Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252
- Evan Z Macosko · Broad Institute, Inc.$32,116,761
Research focus
AdultAmyotrophic Lateral SclerosisAnimal ModelAntisense OligonucleotidesAntisense Oligonucleotide TherapyBiologicalCdk5 GeneCell NucleusCellsCellular AssayCellular BiologyClinicClinical TrialsCytoplasmDesignDisease HeterogeneityDown-RegulationExcisionExhibitsExperimental StudyGenesGeneticGenetic TranscriptionGenomic Signature
Grant awards (3)
Therapeutic targeting of ATXN2 for sporadic amyotrophic lateral sclerosis (ALS)$51,752
F30 · FY2022 · AG · contact PI
Therapeutic targeting of ATXN2 for sporadic amyotrophic lateral sclerosis (ALS)$38,382
F30 · FY2020 · AG · contact PI
Therapeutic targeting of ATXN2 for sporadic amyotrophic lateral sclerosis (ALS)$37,456
F30 · FY2019 · AG · contact PI